Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 7/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | THPO | P40225 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509173 | 1.00 | CYP2C9 (0.55) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL30192384 | 1.00 | CYP2C9 (0.55) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL8021648 | 0.93 | CYP2C9 (0.56) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL8091053 | 0.91 | NR3C2 (0.48) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL6947811 | 0.90 | CYP1A2 (0.56) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL8912184 | 0.90 | NR3C2 (0.47) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL6951166 | 0.89 | CYP2C9 (0.53) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL6952048 | 0.89 | CYP2C9 (0.55) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL7410229 | 0.87 | CYP2C9 (0.66) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL9153822 | 0.86 | CYP2C9 (0.58) | CYP2C9CYP1A2CYP3A4CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156639-A1 | COMPOSITIONS AND METHODS OF TREATMENT USING L-TYPE CALCIUM CHANNEL BLOCKERS AND CHOLINESTERASE INHIBITORS | TRIPPODI-MURPHY CRISTA | 2009-06-18 | — | — | US | claimed |
| US-20090069361-A1 | METHODS OF TREATMENT USING (+)- ISOPROPYL 2-METHOXYETHYL 4-(2-CHLORO-3-CYANO-PHENYL)-1, 4-DIHYDRO-2, 6-DIMETHYL-PYRIDINE-3, 5-DICARBOXYLATE | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| EP-1952824-A1 | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors | Memory Pharmaceuticals Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1684806-B1 | COMPOSITIONS COMPRISING L-TYPE CALCIUM CHANNEL BLOCKERS AND CHOLINESTERASE INHIBITORS | MEMORY PHARM CORP (US) | 2008-06-25 | — | — | EP | claimed |
| US-20080026081-A1 | Methods of Treatment Using (+)-Isopropyl 2-Ethoxyethyl-4-(2-Chloro-3-Cyano-Phenyl)-1,4-Dihydro-2,6-Dimethyl-Pyridine-3,5-Dicarboxylate | MEMORY PHARMACEUTICALS CORPORATION | 2008-01-31 | — | — | US | claimed |
| US-20050153953-A1 | Compositions and methods of treatment using L-type calcium channel blockers and cholinesterase inhibitors | MEMORY PHARMACEUTICAL | 2005-07-14 | — | — | US | claimed |
| EP-0657430-B1 | Isopropyl-(2-methoxyethyl)-4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-piridine-3,5-dicarboxylate | BAYER AG (DE) | 1999-06-02 | — | — | EP | claimed |
| US-5665740-A | Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-09 | — | — | US | claimed |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | SEGENA CORPORATION S.A. (UY) | 2026-05-28 | — | — | US | disclosed |
| EP-4622674-A1 | ENHANCING OLIGONUCLEOTIDE IMMUNOMODULATORY ACTIVITY THROUGH DIANOPHORE LONG-LASTING MODIFICATION: METHODS AND APPLICATIONS | SEGENA CORPORATION S.A. (UY) | 2025-10-01 | — | — | EP | disclosed |
| CN-115645389-B | Application of compound ML1 and derivative thereof in improving activity and function of cerebral cortex | 刘晓栋 | 2024-10-01 | — | — | CN | disclosed |
| US-20240016759-A1 | TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORES | CORIUM, LLC | 2024-01-18 | — | — | US | disclosed |
| US-20230391796-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | SIMON FRASER UNIVERSITY (CA) | 2023-12-07 | — | — | US | disclosed |
| CN-116916916-A | Glycosidase inhibitors and uses thereof | 塞维利亚大学 | 2023-10-20 | — | — | CN | disclosed |
| US-5708177-A | OXIDATION/REDUCTION OF OPPOSITE ENANTIOMERS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-13 | — | — | US | disclosed |
| US-5665740-A | Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-09 | — | — | US | disclosed |
| US-5665740-A | Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate | BAYER AKTIENGESELLSCHAFT (DE) | 1997-09-09 | — | — | US | disclosed |
| CN-1109874-A | Novel substituted dihydropyridine dicarboxylic ester | BAYER AG (DE) | 1995-10-11 | — | — | CN | disclosed |
| CN-1109874-A | Novel substituted dihydropyridine dicarboxylic ester | BAYER AG (DE) | 1995-10-11 | — | — | CN | disclosed |
| CN-1109874-A | Novel substituted dihydropyridine dicarboxylic ester | BAYER AG (DE) | 1995-10-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391796-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, OGT, ENGASE | CYP2C9 1014/4885CYP1A2 835/4885CYP3A4 1371/4885 |
| US-20260146254-A1 | Enhancing Oligonucleotide Immunomodulatory Activity through Dianophore Long-Lasting Modification: Methods and Applications | CD44, ADAR, TLR9 | CYP2C9 4586/4885CYP1A2 4798/4885CYP3A4 4666/4885 |
| US-20240016759-A1 | TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORES | CD69, CUTA, PGRMC2 | CYP2C9 444/4885CYP1A2 1082/4885CYP3A4 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.